Overview: New Modality for Cancer Treatment.
Oncology
; 89 Suppl 1: 33-5, 2015.
Article
em En
| MEDLINE
| ID: mdl-26551305
ABSTRACT
Cancer immunotherapy is now becoming a promising modality of cancer treatment upon the clinical successes of adoptive T-cell transfer and immune checkpoint blockade. At the 30th Nagoya International Cancer Treatment Symposium, Marcel R.M. van den Brink (Memorial Sloan Kettering Cancer Center, MSKCC, New York, N.Y., USA) showed novel strategies to control malignant relapse and graft-versus-host disease, both major obstacles for clinical benefits in allogeneic hematopoietic stem cell transplantation. Alexander M. Lesokhin (MSKCC, New York, N.Y., USA) presented an overview of immune checkpoint blockade, particularly focusing on hematologic malignancies stressing the importance of immunomonitoring to identify biomarkers.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T
/
Imunoterapia Adotiva
/
Transplante de Células-Tronco Hematopoéticas
/
Neoplasias Hematológicas
/
Doença Enxerto-Hospedeiro
/
Vigilância Imunológica
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article